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This paper presents the first two successful cases of pre-implantation gen-
etic diagnosis in Hong Kong and discusses the indications and the advan-
tages over prenatal diagnosis. Patients should be informed about the
procedure and extensively counselled about the possibility of misdiagnosis
and the need for conventional prenatal diagnosis during pregnancy.
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Introduction
Pre-implantation genetic diagnosis (PGD) uses molecular biological techniques
to select genetically normal embryos for replacement to the uterine cavity of a
woman during an assisted reproduction cycle. Such a procedure is indicated
for couples at risk of having babies with serious genetic disorders. The first baby
to undergo PGD1 was born more than 10 years ago and, since then, PGD has
shown an exponential growth in many countries. Currently, more than 50 centres
worldwide are offering PGD for a variety of genetic disorders, including single
gene defects, chromosomal imbalances, and sexing for X-linked diseases.2
The Assisted Reproduction Unit at Queen Mary Hospital (QMH) is the first
unit in Hong Kong to provide a PGD programme. This paper reports the first two
successful PGD cases out of seven treatment cycles performed in 2001 and to
discuss the indications and advantages over prenatal diagnosis. The procedure is
described and the counselling aspect is highlighted.
Case 1
A 28-year-old woman and her 37-year-old husband were referred to the
Subfertility Clinic in October 1998 because of primary infertility due to severe
oligoasthenoteratozoospermia (OAT) for 2 years. Repeated semen analyses
during subfertility examination revealed only one to two motile spermatozoa at
microscopic examination at low magnification. The husband was in good health
and he neither smoked nor drank. There was no previous history of mumps orchitis,
genital trauma, or surgical operation. Clinical examination of the husband
at the Male Infertility Clinic showed slightly atrophic testes of approximately
10 mL on both sides. The epididymis and vas were all normal. His serum follicle
stimulating hormone (FSH) level at that time was 25 mIU/mL (normal range,
1-12 mIU/mL). His wife also enjoyed good health and had a regular menstrual
cycle.
This couple were enrolled into the in vitro fertilisation/embryo transfer (IVF/
ET) programme at QMH and intracytoplasmic sperm injection (ICSI) was
required to assist fertilisation because of the poor semen quality. The first and
second IVF/ICSI treatment cycles were done in December 1999 and August 2000.
The long protocol of ovarian stimulation, gamete handling, and ICSI has been
previously described.3 In the first cycle, 15 of 17 oocytes at metaphase II were
fertilised after ICSI. Only two good quality embryos were available for transfer
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and there were no excess embryos for freezing. In the
second cycle, eight oocytes at metaphase II were fertilised
and cleaved after ICSI. Two good quality embryos were
transferred and there was one frozen embryo from the
second cycle. The woman did not conceive in these two
treatment cycles, however.
The husband subsequently underwent karyotyping and
microdeletion of the Y chromosome assay as part of a
research project to investigate the genetic causes of severe
male infertility.4 The results revealed 47,XYY and no
Y microdeletion. After detailed and extensive counselling,
the couple agreed to undergo a third cycle of IVF/ICSI
with PGD in May 2001 to select embryos without any sex
chromosomal abnormalities for replacement. Only five of
12 oocytes aspirated were microinjected because only five
motile spermatozoa were found after sperm processing. On
day 3 after egg collection, PGD was performed by fluores-
cence in situ hybridisation (FISH) for chromosomes X and
Y on two good quality embryos from the fresh cycle and
the frozen embryo from the second cycle.
Two of the biopsied embryos, one from the fresh cycle
and one from the frozen cycle, had two X chromosomes
and no Y chromosome (Fig 1). Diagnosis could not be made
in the third embryo because of the lack of a nucleus in the
biopsied cell. The two normal embryos were transferred to
the wife on day 4 after egg collection and she subsequently
conceived. The wife declined to have amniocentesis because
of the risk of miscarriage after the procedure. The antenatal
course was uneventful and a baby girl was born vaginally in
February 2002. A normal female karyotype was confirmed
after delivery.
Case 2
A 26-year-old woman and her 36-year-old husband were
referred to the Subfertility Clinic in February 1998 because
of primary infertility for 3 years due to severe OAT. Re-
peated semen analyses showed one to two motile spermato-
zoa at microscopic examination with low magnification. The
husband was in good health and he neither smoked nor drank.
There was no previous history of mumps orchitis, genital
trauma, or surgical operation. Clinical examination of the
husband did not show any abnormalities and his hormonal
profile including FSH, luteinising hormone, testosterone,
and prolactin level was normal. Karyotyping revealed
45,XY with Robertsonian translocation of chromosomes
13 and 21 and there was no Y microdeletion. The wife
had undergone two IVF/ICSI cycles in March 1999 and
November 2000 without PGD being performed. She had
three frozen embryos from the second cycle.
After detailed and extensive counselling, the couple con-
sented to have PGD done on the three frozen embryos after
they were thawed in June 2001 in a hormonal replacement
Fig 1. Fluorescence in situ hybridisation result of the first birth
Embryo 1 Blastomere 1 Blastomere 2
Embryo 2 Blastomere 1 Blastomere 2
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cycle. Fluorescence in situ hybridisation was performed
using a five-coloured probe panel (MultiVysion PGT; Vysis,
Downers Grove, United States) consisting of multicolour
probes for chromosomes 13, 18, 21, X, and Y. Results
demonstrated that none of the three embryos had consistent
normal signals for the chromosomes tested. Therefore,
no embryos were replaced in this cycle. Further analysis of
the embryos showed that all embryos were abnormal
with either chaotic, diploid mosaic, or abnormal mosaic
patterns.5 The third cycle of IVF/ICSI/PGD was done in
December 2001. The patient had good ovarian response
and nine of 15 oocytes at metaphase II were normally
fertilised after ICSI. Pre-implantation genetic diagnosis
was performed on eight good quality embryos on day
3 after egg collection. Fluorescence in situ hybridisation
for chromosomes 13 and 21 demonstrated two normal
embryos while other abnormal embryos were found to
have mosaic, monosomy 21/mosaic, or chaotic patterns on
further analysis (Fig 2). These two normal embryos were
replaced and the woman was found to be pregnant with
a single intrauterine foetus. Amniocentesis in April 2002
confirmed normal karyotype of the foetus and a healthy
baby girl was delivered in October 2002 at 41 weeks of
gestation.
Indications
Pre-implantation genetic diagnosis is indicated for couples
at risk of having babies with serious genetic disorders, which
can be due to chromosomal abnormalities or gene defects.
Approximately 20% of male infertility can now be explained
by abnormalities in mitotic and/or meiotic chromosomes.
An abnormal karyotype has been shown in 13.7% of men
with azoospermia and 4.6% of men with oligozoospermia.6
Sex chromosome abnormalities (mainly 47,XXY) are
predominantly found in the azoospermic group, whereas
autosome anomalies (Robertsonian and reciprocal trans-
locations) are mainly present in oligozoospermic men. The
men in the two couples described here were found to have
abnormal karyotypes—it is usual for subfertile men with a
sperm count of <5 million per mL to check the karyotype
and Y microdeletion prior to IVF treatment. In this
programme, nearly 20% of the patients screened had
abnormal karyotypes.7 Chromosomal abnormalities are
also increased for couples with a history of having chromo-
somally abnormal babies, history of recurrent miscarriages,
or in subfertile couples undergoing IVF treatment.8
In the first case, the husband had a karyotype of 47,XYY.
The frequency of spermatozoa with abnormal sex chromo-
somes (24,XY and 24,YY) in fertile controls are approxi-
mately 0.5%, whereas this frequency increases in men with
47,XYY karyotype and ranges from 0.6% to 15.0%.9-11
During the ICSI procedure, it is impossible to distinguish a
spermatozoon carrying abnormal chromosomal makeup
from another one with normal chromosomal content as
both of them may be phenotypically normal. Therefore,
karyotypes of the resulting embryos/babies may have
abnormal sex chromosome numbers such as 47,XXY or
47,XYY when PGD is not performed.
Balanced carriers of Robertsonian translocations, which
has a prevalence of 1 in 1000, are phenotypically normal
but may present with infertility, recurrent miscarriage, or
pregnancy with an abnormal phenotype after abnormal seg-
regation of the translocated allele at meiosis. Unbalanced
spermatozoa can be found in 8% to 26% of spermatozoa
from translocation carriers.12-14 Approximately half of the
embryos from these translocation carriers are chromoso-
mally normal whereas the remaining are aneuploidy or
chaotic.12 Therefore, there is a high chance for a woman
Fig 2. Fluorescence in situ hybridisation result of the second
birth
Embryo 1 (normal for chromosomes 13, 21)
Embryo 2 (normal for chromosomes 13, 21)
Embryo 3 (monosomy 21)
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to have an affected pregnancy if PGD is not performed.
After PGD selection, there is a significant reduction in
spontaneous miscarriage from 95% to 13% in patients
with translocations.15 In the second case, the karyotype of
the husband was 45,XY with Robertsonian translocation of
chromosomes 13 and 21 and the resulting embryos can be
monosomy 13, monosomy 21, trisomy 13, trisomy 21,
45 rob (13, 21) or normal.
The thalassaemia syndromes (α- or β-thalassaemia)
are the most common monogenetic diseases and are most
prevalent in South-East Asia. Couples carrying the same
thalassaemia trait, that is either α- or β-thalassaemia trait,
have a 25% chance of having a baby affected by the homo-
zygous state of the disease. Homozygous α-thalassaemia
causes hydrops foetalis and homozygous β-thalassaemia
causes severe postnatal anaemia that necessitates life-
long blood transfusion. Thus prenatal diagnosis or PGD is
indicated for these individuals.
The observations of a significant incidence of aneuploidy
in early human embryos lead to the application of PGD
techniques for patients who had a poor prognosis after IVF
treatment such as advanced maternal age and repeated
implantation failure. The chromosomes selected for aneu-
ploidy screening are those commonly seen as trisomic in
spontaneous abortions and include chromosomes X, Y, 13,
18, and 21. The clinical pregnancy rate per embryo transfer
was 36% for advanced maternal age and 11% for repeated
implantation failure.2 Based on these results, it seems that
aneuploidy screening offers little advantage to women who
have repeated implantation failure during IVF treatment.
Pre-implantation genetic diagnosis has been performed
for sex selection for family balancing16 and detection of genes
for adult-onset diseases such as early-onset Alzheimer
disease.17 Pre-implantation genetic diagnosis has also been
used to select a human leukocyte/lymphocyte antigen
(HLA)–compatible donor from embryos without the genetic
mutation so as to provide stem cells for affected siblings in
a family with Fanconi or β-thalassaemia anaemia.18 These
indications are controversial, however, and have aroused
much debate about the associated ethical issues.19-20
Advantage of pre-implantation genetic diagnosis
over prenatal diagnosis
The above genetic disorders can also be detected by con-
ventional prenatal testing, including ultrasound, amnio-
centesis or chorionic villus sampling. The majority of
women with affected foetuses undergo termination of
pregnancy in the second trimester of pregnancy, although
some do not agree to termination of pregnancy because of
psychological or religious reasons. Pre-implantation genetic
diagnosis is an alternative to prenatal diagnosis and has the
advantage that the couples do not need to have the physical
and psychological trauma of undergoing termination of
pregnancy.
A survey of attitudes towards PGD in women at risk of
giving birth to a child with α- or β-thalassaemia has been
performed in Hong Kong.21 Of 205 questionnaires sent out,
141 completed questionnaires were analysed. The results
indicated that 82.3% of the women considered PGD either
the same as or better than conventional prenatal diagnosis
and women with an affected child or subfertility problems
were more willing to accept PGD and to undergo this
procedure in their future pregnancies. Avoidance of termin-
ation of an affected pregnancy was regarded as the most
important advantage of PGD. This study highlights the
need for implementation of PGD as an alternative for these
women.
Procedure
Couples requiring PGD have to undergo the standard
IVF/ET treatment with ICSI, which involves injection of a
single spermatozoon into the cytoplasm of an oocyte.
This method of fertilisation eliminates the possibility of
contamination by the husband’s spermatozoa and reduces
the chance of misdiagnosis in PGD. The zygotes obtained
are cultured for 48 hours, when the good quality embryos
should be at the six- to eight-cell stage. One or two
blastomeres from each good quality embryo are then
taken out using laser micromanipulation. A hole is made on
the zona pellucida of the embryos to be biopsied with an
infrared (1480 nm) laser. One to two blastomeres are
removed from the embryos through the hole using a fine
needle with internal diameter of 35 µm (Fig 3). The
nucleus of the each blastomere is obtained by successively
lysing the cell with hypotonic potassium chloride solution
and hydrochloric acid-Tween-20 solution.
The genetic make-up of the biopsied cells is analysed
by genetic tests such as FISH or polymerase chain reaction
(PCR). The first successful report on PGD described the use
Fig 3. Embryo biopsy
Cleaving embryo
Holding pipette
Blastomere
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of PCR to sex embryos from couples at risk of sex-linked
diseases.1 With advances in molecular biology, FISH was
introduced and replaced PCR for sexing of embryos because
of improved accuracy. Fluorescence in situ hybridisation
is indicated for numerical and structural chromosomal
abnormalities while PCR is mainly reserved for monogenic
diseases such as cystic fibrosis and thalassaemia. The gen-
etic tests usually take 8 to 26 hours, depending on the type
of tests performed. Genetically normal embryos that con-
tinue to grow after biopsy will be selected for replacement
to the woman, while the genetically abnormal embryos will
be discarded.
Fluorescence in situ hybridisation is often used for
aneuploidy screening in PGD. One of the limitations of
using this technique is the difficulty in the simultaneous
detection of all the chromosomes in a single cell. It is
believed that the benefit of aneuploidy screening may be
increased if more chromosomes are analysed. Therefore,
comparative genomic hybridisation has been applied to a
single blastomere biopsied from human embryos for com-
plete karyotyping and has resulted in the first birth from an
embryo that has been fully karyotyped prior to transfer.22
The analysis of this technique, however, takes at least 5 days
to complete because of the long hybridisation time required
and the laborious analysis of template chromosomes.
Couselling
Patients should be extensively counselled about the
indication, procedure, and accuracy of PGD prior to the
treatment cycle. The rate of misdiagnosis is approximately
1.8% (0.9% for FISH and 3.4% for PCR).2 Patients should
also be informed of the complications and risks of IVF/
ICSI and accept that there may not be any normal embryos
for replacement after PGD. In most programmes, prenatal
testing such as amniocentesis is advised to confirm the
genetic diagnosis made during PGD. However, some
pregnant women may decline the amniocentesis because
of the associated risk of miscarriage after the procedure.
Although the neonatal outcome of PGD seems to be
reassuring,23 long-term paediatric follow-up would be
desirable for monitoring the effects on growth and mental
development.
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